Journal of Clinical Oncology, Vol 5, 1262-1274, Copyright © 1987 by American Society of Clinical Oncology

ARTICLES

Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival

DK Wagner, J Kiwanuka, BK Edwards, LA Rubin, DL Nelson and IT Magrath

We have been able to detect soluble interleukin-2 receptors (IL-2R) in pretreatment sera from 80 patients with undifferentiated lymphoma (predominantly Burkitt's lymphoma) and lymphoblastic lymphoma. The demonstration of IL-2R in lymphoma-derived cell lines by immunoprecipitation and direct staining indicates that IL-2R is synthesized by the tumor cells. Comparisons were made with two other subject groups: 42 sarcoma patients and 17 normal individuals. The distribution of soluble IL-2R values for lymphoma patients (geometric mean, 1,132 U/mL) was significantly greater than that of sarcoma patients (geometric mean, 332 U/mL; P = .0001) or normal individuals (geometric mean, 238 U/mL; P = .0001). Patients with undifferentiated lymphoma stages B, C, and D had significantly higher soluble IL-2R values (geometric mean, 1,648 U/mL) than stages A and AR (geometric mean, 706 U/mL; P = .0001) or lymphoblastic lymphoma (geometric mean, 826 U/mL; P = .0002). Within the lymphoma group, the soluble IL-2R level was found to be the most significant prognostic indicator of disease-free interval and survival when compared with other previously recognized factors such as histology, stage, bone marrow involvement at presentation, lactic dehydrogenase (LDH), uric acid (UA), and age. No factor was significantly associated with response to therapy, ie, the initial achievement of complete remission (CR) status, although small numbers of patients with a partial response limit interpretation. Soluble IL-2R levels were measured serially in two patients and were found to be elevated at presentation or relapse and to decrease to normal levels during periods of disease remission. IL-2R appears to reflect tumor burden and may prove to be a useful and specific marker for lymphoid tumors.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Ennishi, M. Yokoyama, Y. Terui, H. Asai, S. Sakajiri, Y. Mishima, S. Takahashi, H. Komatsu, K. Ikeda, K. Takeuchi, et al. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy Ann. Onc., March 1, 2009; 20(3): 526 - 533. [Abstract] [Full Text] [PDF]

				Y. Moon, Y. Kim, M. Kim, J. Lim, C. S. Kang, W. I. Kim, S. I. Shim, N. G. Chung, Y. H. Park, W. S. Min, et al. Plasma Soluble Interleukin-2 Receptor (sIL-2R) Levels in Patients with Acute Leukemia Ann. Clin. Lab. Sci., October 1, 2004; 34(4): 410 - 415. [Abstract] [Full Text] [PDF]

				C. Akin, L. B. Schwartz, T. Kitoh, H. Obayashi, A. S. Worobec, L. M. Scott, and D. D. Metcalfe Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology Blood, August 15, 2000; 96(4): 1267 - 1273. [Abstract] [Full Text] [PDF]

				M. Shaarawy, N. A. Darwish, and O. Abdel-Aziz Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Gestrational Trophoblastic Diseases Reproductive Sciences, January 1, 1996; 3(1): 39 - 46. [Abstract] [PDF]

				M. A. Wasik, E. C. Vonderheid, R. D. Bigler, R. Marti, S. R. Lessin, M. Polansky, and M. E. Kadin Increased Serum Concentration of the Soluble Interleukin-2 Receptor in Cutaneous T-Cell Lymphoma: Clinical and Prognostic Implications Arch Dermatol, January 1, 1996; 132(1): 42 - 47. [Abstract] [PDF]

				B. D. Goldman, S.-K. Oh, B. E. Davis, M. E. Kadin, B. J. Poiesz, and H. K. Koh Serum Soluble Interleukin 2 Receptor Levels in Erythrodermic Cutaneous T-Cell Lymphoma Correlate With Response to Photopheresis-Based Treatment Arch Dermatol, September 1, 1993; 129(9): 1166 - 1170. [Abstract] [PDF]

				M. A. Simpson, T. M. Young-Fadok, P. N. Madras, R. B. Freeman, R. A. Dempsey, D. Shaffer, D. Lewis, R. L. Jenkins, and A. P. Monaco Sequential Interleukin 2 and Interleukin 2 Receptor Levels Distinguish Rejection From Cyclosporine Toxicity in Liver Allograft Recipients Arch Surg, June 1, 1991; 126(6): 717 - 720. [Abstract] [PDF]

				L. A. Rubin and D. L. Nelson The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application Ann Intern Med, October 15, 1990; 113(8): 619 - 627. [Abstract] [PDF]

				L. Marcon, L. A. Rubin, C. C. Kurman, M. E. Fritz, D. L. Longo, T. Uchiyama, B. K. Edwards, and D. L. Nelson Elevated Serum Levels of Soluble Tac Peptide in Adult T-Cell Leukemia: Correlation with Clinical Status during Chemotherapy Ann Intern Med, August 15, 1988; 109(4): 274 - 279. [Abstract] [PDF]